Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Broadens License to Inpharmatica s PharmaCarta Platform

NEW YORK, Jan. 25 (GenomeWeb News) - Inpharmatica said today that it has expanded an informatics agreement with Pfizer that the companies initiated in 2000.

 

Under the expanded agreement, Pfizer will use four components of Inpharmatica's PharmaCarta technology platform. These components are in addition to Pfizer's current subscription to Biopendium, which the company first licensed five years ago.

 

Pfizer will gain access to Inpharmatica's StarLite database of curated medicinal chemistry information; to its DrugStore database of all known drugs, linked with their targets; and to the Admensa ADME prediction platform.

 

Inpharmatica will also use its proprietary PharmaCarta technology for a druggability assessment study.

 

Financial terms of the new agreement were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more